MAXCYTE, INC.MXCTEarnings & Financial Report
MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.
Revenue
$5.7M
Gross Profit
$4.2M
Operating Profit
$-12.3M
Net Profit
$-10.3M
Gross Margin
73.9%
Operating Margin
-214.1%
Net Margin
-178.7%
YoY Growth
2.8%
EPS
$-0.10
MAXCYTE, INC. Q1 FY2025 Financial Summary
MAXCYTE, INC. reported revenue of $5.7M (up 2.8% YoY) for Q1 FY2025, with a net profit of $-10.3M (down 7.7% YoY) (-178.7% margin).
Key Financial Metrics
| Total Revenue | $5.7M |
|---|---|
| Net Profit | $-10.3M |
| Gross Margin | N/A |
| Operating Margin | -214.1% |
| Report Period | Q1 FY2025 |
Revenue Breakdown
MAXCYTE, INC. Q1 FY2025 revenue of $5.7M breaks down across 2 segments, led by Products at $5.3M (92.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $5.3M | 92.6% |
| Other | $427.0K | 7.4% |
MAXCYTE, INC. Revenue by Segment — Quarterly Trend
MAXCYTE, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Products | $4.2M | $4.0M | $5.3M | $5.3M |
| Other | $634.0K | $650.0K | $555.0K | $427.0K |
MAXCYTE, INC. Annual Revenue by Year
MAXCYTE, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $21.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $21.0M |
| 2024 | $22.2M |
| 2023 | $19.5M |
| 2022 | $28.7M |
MAXCYTE, INC. Quarterly Revenue & Net Profit History
MAXCYTE, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $4.8M | -20.9% | $-9.6M | -200.5% |
| Q3 FY2025 | $4.6M | -18.0% | $-12.4M | -269.7% |
| Q2 FY2025 | $5.8M | +17.3% | $-12.4M | -212.2% |
| Q1 FY2025 | $5.7M | +2.8% | $-10.3M | -178.7% |
| Q4 FY2024 | $6.1M | +27.3% | $-10.6M | -175.0% |
| Q3 FY2024 | $5.6M | +35.0% | $-11.6M | -205.9% |
| Q2 FY2024 | $5.0M | -11.7% | $-9.4M | -188.8% |
| Q1 FY2024 | $5.6M | +12.5% | $-9.5M | -170.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.6M | $5.0M | $5.6M | $6.1M | $5.7M | $5.8M | $4.6M | $4.8M |
| YoY Growth | 12.5% | -11.7% | 35.0% | 27.3% | 2.8% | 17.3% | -18.0% | -20.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $257.9M | $251.5M | $248.6M | $239.5M | $230.0M | $219.8M | $213.5M | $202.5M |
| Liabilities | $31.6M | $30.2M | $35.3M | $33.2M | $30.5M | $29.0M | $33.2M | $31.0M |
| Equity | $226.4M | $221.3M | $213.3M | $206.3M | $199.4M | $190.7M | $180.3M | $171.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-10.6M | $-4.8M | $-4.4M | $-7.8M | $-14.4M | $-9.9M | $-7.5M | $-2.7M |